NCT04593784 - Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

August 26, 2023

Study Completion Date

August 26, 2023

Conditions

Healthy

Interventions

DRUG

Ciraparantag

Ciraparantag: 180 mg, intravenous

DRUG

Placebo

Placebo: 0.9% sodium chloride, intravenous

DEVICE

Point-of-Care Coagulometer (investigational device)

Perosphere Technologies' Point of Care (POC) Coagulometer Device will be used to measure whole blood clotting time.

Trial Locations (3)

Qps-Mra, Llc., South Miami

ICON Early Phase Services, LLC, San Antonio

Frontage Clinical Services, Secaucus